Yüklüyor......
An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre
BACKGROUND: Treatment for advanced non-small-cell lung cancer (nsclc), especially in patients with wild-type EGFR, remains limited. Recently, erlotinib, a tyrosine kinase inhibitor (tki) targeting EGFR mutation, was approved as second-line treatment in EGFR wild-type nsclc. Despite evidence of bette...
Kaydedildi:
| Yayımlandı: | Curr Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Multimed Inc.
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4462537/ https://ncbi.nlm.nih.gov/pubmed/26089726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2296 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|